
In a study, 1657 eligible patients with advanced gastric or gastro-oesophageal junction adenocarcinoma received tislelizumab or placebo in combination with chemotherapy. The tislelizumab plus chemotherapy group demonstrated significantly improved overall survival compared to the placebo plus chemotherapy group, both in patients with a PD-L1 TAP score of ≥5% (median 17.2 months vs 12.6 months) and in all randomized patients (median 15.0 months vs 12.9 months). The tislelizumab regimen also exhibited a manageable safety profile. These findings support the potential of tislelizumab as a beneficial treatment option for this patient population.
Like
Save
Share